Stanley Druckenmiller, Ken Griffin and Cathie Wood all hold Eli Lilly shares, according to their reported portfolios. Druckenmiller opened a position in the second quarter, Griffin increased his stake by more than 200%, and Wood holds shares through two Ark ETFs.
Druckenmiller bought 12,380 shares, equal to 0.2% of his portfolio; Griffin now holds 945,456 shares, or 0.1%. Wood's Ark Innovation ETF holds 39,162 shares (0.4% of that fund), while her Ark Genomic Revolution ETF holds 67,402 (3.4%).
Eli Lilly's Mounjaro and Zepbound generated more than $14 billion in combined revenue in the latest quarter, the article says. It also reports that the weight-loss-drug market is expected to approach $100 billion by the end of the decade and that Lilly launched its first weight-loss pill a few months earlier.
